Click Here to Register »

Executive Sponsor

Cambridge Consultants

Technology Sponsors

Credence MedSystems
Enable Injections
Insulet Corporation
Salvona Technologies
Sensile Medical


Beuhler Motor

Soapbox Sponsors


Media Partners

On Drug Delivery
BioPharm Insight
Bloomberg Brief
Can Biotech
Clinical Informatics News
Drug Development & Delivery
Fierce Drug Delivery
Larta Institute
Life Science Leader
Massachusetts Life Sciences Center
MCD Group
Medical News Today
Medtech Boston
Technology Networks


Monday, October 5, 2014

  • 8:00 am

  • Breakfast, Registration, Partnering Meetings

  • 8:45 am

  • Chair’s Opening Remarks

    Chair’s Opening Remarks

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 9:00 am

  • Opening Keynote Address on Nanotechnology

    Opening Keynote Address on Nanotechnology

    Robert Langer, PhD
    David H. Koch Institute Professor, MIT

  • 9:50 am

  • Industry Keynote

    We are delighted to welcome our 2015 industry keynote, Dr Bahija Jallal, EVP, MedImmune. Dr Jallal is responsible for biologics research, development and clinical activities. As part of AstraZeneca’s Senior Executive Team, she is tasked with advancing the biologic organization’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders and pain. Joining Dr Jallal on the stage is PODD veteran, Dr Anand Subramony, VP, Drug Delivery & Device Development, MedImmune.

    Bahija Jallal, PhD
    EVP, Head of MedImmune

    Anand Subramony, PhD
    VP, Drug Delivery & Device Development, MedImmune

  • 10:30 am

  • Networking Break and Partnering Meetings

  • 11:15 am

  • Licensing Drug Delivery Technologies for Oncology Therapeutics

    In this panel, we will hear from business development and licensing executives regarding current level of interest in drug delivery technologies for pipeline and launched drugs.

    • Licensing improved formulations of off-patent cancer drugs vs. enabling platform technologies for NCEs
    • Criteria used to evaluate novel oncology drug delivery systems
    • What stage and type of data is most attractive to pharmaceutical partners?
    • Types of formulations and technology platforms actively sought:
      • Nanotechnology-based/Nanomedicine
      • Antibody drug conjugates
      • Sustained release depots/implants
    • Structuring partnerships – platform vs. product licenses, option-based agreements, regional deals

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

    Neela Patel, PhD
    Director, Licensing-Search and Evaluation, Abbvie

    Denis Patrick, PhD
    Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer

    Vahe Bedian, PhD
    Director, Oncology External Projects, AstraZeneca

  • 12:00 pm

  • Sanofi Drug Delivery Case Study

    Paul Jansen
    VP, Medical Device Development, Sanofi

  • 12:45 pm

  • Luncheon and Partnering Meetings

  • 2:00 pm

  • Drug Delivery Presentations in Three Tracks

    Track OneNon-Injectable Formulation Technologies
    Chaired by:
    Fernando Sallés, PhD
    VP, Head of Global Search, Teva Pharmaceuticals

    Track TwoInjectable Formulation Technologies
    Chaired by:
    Richard Korsmeyer, PhD
    Executive Director, Advanced External Projects, Technology & Innovation Group, Pfizer

    Track ThreeDrug Delivery Device Technologies
    Chaired by:
    Tomas Landh MSc, PhD
    VP, Innovation Sourcing, Novo Nordisk

    If you are interested in presenting in one of the tracks, please contact Meredith Sands at

  • 6:00 pm

  • Partnering Meetings – 45 minutes


Tuesday, October 6, 2014

  • 8:00 am

  • Breakfast & Partnering Meetings

  • 8:30 am

  • Chair’s Welcome

    Chair’s Welcome

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 8:45 am

  • CEO Keynote

    Stéphane Bancel
    CEO, Moderna Therapeutics

  • 9:30 am

  • Utilizing Nanotechnology to Advance Targeted Therapies and Personalized Medicine

    Omid Farokhzad, MD
    Associate Professor, Harvard Medical School

  • 10:15 am

  • Networking Break & Partnering Meetings

  • 11:00 am

  • Technology Spotlight

    Sponsored by:
    3M Drug Delivery Systems

  • 11:20 am

  • Large Volume Drug Delivery – Are Patch Pumps the Answer?

    Due to the increasing need for improved parenteral delivery of high dose pharmaceuticals, especially biologics, a number of new wearable devices have been developed, such as patch pumps and bolus injectors. These devices enable self-administration and eliminate the need for multiple injections or infusions. This panel will discuss the current generation of wearable injection devices and the opportunities and challenges that lie ahead.

    • Key drawbacks of current devices – what should next generation devices address?
    • Beyond insulin, will patch pumps be cost-effective for other drugs such as mAbs?
    • How does the size of the device affect patient acceptability?
    • Implementing acceptance of wearable technology
    • Selecting the appropriate device, and device manufacturer-partner

    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation, Amgen

    Michael Graffeo
    VP, Business Development, Drug Delivery, Insulet Corporation

    David Haase
    Senior Manager, Device Development, Genentech

    Andrew Hamer, MD
    VP, Medical Affairs, Capricor Therapeutics

    Michael Hooven
    President and CEO, Enable Injections, LLC

    Anand Subramony
    VP, Drug Delivery & Device Development, Biopharmaceutical Development, MedImmune

    Speaker TBD
    Cambridge Consultants

  • 12:00 pm

  • Fifth Annual Company Spotlights

    In this session, we highlight three companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation

    Sanofi-Genzyme BioVentures
    Ann DeWitt, PhD
    Senior Director of Investments

    Abla Creasey, PhD
    Senior Scientific Director, Drug Delivery Systems/PDMS

  • 1:00 pm

  • Luncheon and Partnering Meetings

  • 2:00 pm

  • Can RNA-based Therapeutics Really Deliver?

    Despite the therapeutic promise of RNA therapeutics, efficient and safe drug delivery remains a significant challenge.   These therapeutics tend to have unfavorable physicochemical properties including negative charges, large molecular weight and size, and instability.   A number of carrier systems are being developed for RNA therapeutics, including polymers, lipids, and conjugates, but selection of the delivery system depends on the therapeutics properties, type of target cells and the desired delivery route.   This panel will discuss:

    • Key hurdles related to delivery of RNA therapeutics: siRNA, mRNA, RNAi
    • Delivery strategies and examples of recent successes
    • Collaborative approaches/models that are working
    • Commercialization prospects given low success rate of RNA drugs to-date

    Jessica Ballinger
    Senior Director, Protein Pharmaceutical Development, Biogen Idec

    Abla Creasey
    Senior Scientific Director, Drug Delivery Systems/PDMS, Janssen

    Dave Rozema
    VP, Chemistry, Arrowhead Research Corporation

  • 2:45 pm

  • DDS Technology Soapbox@PODD sponsored by Pfizer

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    If you are interested in presenting on the Soapbox, please contact Meredith Sands at

  • 3:45 pm

  • Improving Drug Delivery to the Back of the Eye

    There is an increasing need to successfully treat posterior eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy. Drug delivery to the back of the eye is challenging not only because of the anatomy of the eye and associated static and dynamic barriers, but also due to the growth of biologic therapeutics, and the challenges of delivering and stabilizing these more complex, large molecules. This panel will discuss goals and challenges of delivery, types of delivery systems showing promise for more effective delivery, and the benefits of collaborating in this space.

    James J. Cunningham, PhD
    Director, Ocular Drug Delivery, Allergan

    Justin Hanes, PhD
    Lewis J. Ort Professor, Director, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

    Jaymin Shah, PhD
    Research Fellow, Pfizer